Expert Joel Neal, MD, PhD, speaks to the management of a 64-year-old man diagnosed with EGFR exon20 insertion–positive NSCLC.
EP. 1: A Case of EGFR Exon 20 Insertion–Positive NSCLC
A case of a 64-year-old man with non–small cell lung cancer, who tested positive for an EGFR exon 20 insertion mutation after progression on frontline therapy.
EP. 2: Optimizing Molecular Testing and Treatment Strategies in NSCLC
Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.
EP. 3: EGFR Exon 20 Insertion–Positive NSCLC: Overview of Treatment Options
Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.
EP. 4: Novel Second-Line Therapy for EGFR Exon 20 Insertion-Positive NSCLC
A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.
EP. 5: EGFR Exon 20 Insertion–Positive NSCLC: CHRYSALIS and EXCLAIM Trial Outcomes
The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.
EP. 6: Experience With Amivantamab and Mobocertinib in EGFR Exon 20 Insertion–Positive NSCLC
Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.
EP. 7: Future of Targeting EGFR Exon 20 Insertion Mutations in NSCLC
Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing.
2 Clarke Drive Cranbury, NJ 08512